INCR Stock Analysis: Buy, Sell, or Hold?
INCR - Intercure Ltd. Ordinary Shares
$5.42
0.16 (3.04%)
▲
5d:
-6.23%
30d:
+485.76%
90d:
+431.37%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When INCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INCR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INCR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INCR is currently trading at $5.42, which is considered extended relative to its 30-day fair value range of $0.41 to $4.93.
Technical Outlook: Technically, INCR is in a uptrend. Immediate support is located at $4.80, while resistance sits at $6.10. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: INCR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.56 (+519.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INCR is in a uptrend. Immediate support is located at $4.80, while resistance sits at $6.10. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: INCR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.56 (+519.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.41 -
$4.93
Company Quality Score
34/100
(SELL)
Options IV Signal
47th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
35.4%
All Signals
- BEARISH: Price extended above range (+9.9% above its trading range)
- NEUTRAL: Options fairly priced (IV 47th percentile)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 519.2% below Wall St target ($33.56)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.41 -
$4.93
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.86
(15.8%)
Support & Resistance Levels
Support Level
$4.80
Resistance Level
$6.10
Current Trend
Uptrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.18
Wall Street Target
$33.56
(+519.2%)
Revenue Growth (YoY)
23.9%
Earnings Growth (YoY)
-84.7%
Profit Margin
-13.2%
Share & Embed Analysis
Last updated: September 07, 2026 3:40 AM ET
Data refreshes hourly during market hours. Next update: 4:40 AM
Data refreshes hourly during market hours. Next update: 4:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 61 BUY |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 77 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 41 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 44 HOLD |
